Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stitch device aims to seal vein holes faster and safer

NCT ID NCT07554976

Disease control Sponsor: Suzhou Hengruihongyuan Medical Technology Co. LTD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medical device that uses stitches to close the hole in a vein after a catheter procedure. About 136 adults aged 18 to 80 who need vein access for heart or blood vessel treatments will take part. The goal is to see if the device stops bleeding quickly and safely compared to standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 80 years 2. Patients eligible for interventional catheter-based examination or treatment via common femoral artery puncture using sheaths sized 5F to 21F 3. Signed by the patient personally or by their legal representative on the Informed Consent Form Exclusion Criteria: 1. Known pregnancy or lactation period; 2. Diameter of the common femoral artery on the puncture side \< 5 mm; 3. Concurrent participation in another clinical research study; 4. Known allergy to any device component, and/or contraindications to contrast agents or anticoagulants; 5. Vascular injury at the access site; 6. Infection of the inguinal puncture site; 7. Morbid obesity (BMI ≥ 40 kg/m²); 8. Lower extremity vascular ultrasound for assessment of common femoral artery stenosis ≥50%; 9. Presence of femoral artery aneurysm, arteriovenous fistula, or pseudoaneurysm in the common femoral artery; 10. Previous use of clip-based vascular closure devices at the ipsilateral arterial access site; 11. Hematoma at the ipsilateral arterial access site; 12. Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Percutaneous intervention via common femoral vein are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Percutaneous intervention via common femoral vein

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongshan Hospital, Fudan University (Lead Site)

    RECRUITING

    Shanghai, China